세계의 건강기능식품 CDMO 시장-성장, 장래 전망, 경쟁 분석(2023-2031년)

The nutraceuticals CDMO (Contract Development and Manufacturing Organization) market is experiencing substantial growth due to increasing demand for customized nutraceutical products and the outsourcing of manufacturing and development processes. This market involves the provision of contract services by specialized CDMOs to nutraceutical companies for formulation development, manufacturing, packaging, and other related services. The market revenue for nutraceuticals CDMO is projected to grow significantly in the coming years, driven by the expanding nutraceutical industry and the need for cost-effective and efficient manufacturing solutions.The global nutraceuticals CDMO market is projected to grow at a CAGR of 7.9% during the forecast period of 2023 to 2031. This growth is attributed to factors such as the rising consumer awareness about health and wellness, the growing aging population, and the increasing prevalence of chronic diseases. Nutraceutical companies are increasingly relying on CDMOs to leverage their expertise, capabilities, and infrastructure to accelerate product development and streamline manufacturing processes.

Increasing Demand for Customized Nutraceutical Products

The nutraceuticals market is witnessing a surge in the demand for customized products that cater to specific consumer needs. This driver is propelled by several factors, including shifting consumer preferences, a growing focus on preventive healthcare, and the rising awareness of the potential health benefits offered by nutraceuticals. Consumers today seek personalized and targeted solutions that address their unique health concerns and goals. This demand for customization creates a significant opportunity for nutraceutical companies to offer tailored products. CDMOs play a pivotal role in meeting this demand for customization. With their expertise in formulation development and understanding of the latest market trends, CDMOs can help nutraceutical companies create innovative products that align with consumer preferences. They provide valuable insights into ingredient selection, dosage forms, and delivery systems that optimize the effectiveness and appeal of the products. By collaborating with CDMOs, nutraceutical companies can develop unique and differentiated offerings that resonate with their target consumers.

Outsourcing of Manufacturing and Development Processes

A prominent driver in the nutraceuticals CDMO market is the increasing trend of outsourcing manufacturing and development processes by nutraceutical companies. This driver is primarily motivated by the desire to streamline operations, reduce costs, and focus on core competencies such as marketing, sales, and product innovation. By partnering with CDMOs, nutraceutical companies can leverage their specialized capabilities and infrastructure to optimize manufacturing processes. CDMOs possess advanced equipment, facilities, and technical expertise to ensure efficient production and high-quality standards. They offer end-to-end solutions, including formulation development, ingredient sourcing, manufacturing, packaging, and regulatory compliance. Outsourcing manufacturing and development processes to CDMOs provides nutraceutical companies with flexibility and scalability. They can adapt to changing market demands and efficiently manage fluctuations in production volumes without incurring significant capital investments. Moreover, CDMOs can offer cost efficiencies through economies of scale, shared resources, and expertise in supply chain management.

Regulatory Compliance and Quality Assurance

Regulatory compliance and quality assurance are crucial drivers in the nutraceuticals CDMO market. The nutraceuticals industry is subject to stringent regulatory requirements to ensure product safety, efficacy, and compliance with regional or international standards. Compliance with these regulations is vital to protect consumer health and maintain the reputation of nutraceutical companies. CDMOs play a critical role in supporting nutraceutical companies in meeting these regulatory standards. They possess in-depth knowledge of the regulatory landscape and can guide companies through complex requirements. CDMOs facilitate adherence to Good Manufacturing Practices (GMP) and conduct quality assurance testing to ensure that products meet the necessary specifications and standards. By partnering with CDMOs, nutraceutical companies can mitigate the risks associated with regulatory non-compliance. CDMOs' expertise in quality control, documentation, and regulatory submissions ensures that products are developed, manufactured, and distributed in accordance with regulatory guidelines. This driver is driven by the increasing focus on consumer safety, the need to adhere to evolving regulatory frameworks, and the potential legal and financial consequences of non-compliance.

Regulatory Compliance Challenges

One of the potential restraints in the nutraceuticals CDMO market is the complex and ever-changing regulatory landscape. The nutraceutical industry is subject to various regulations and guidelines imposed by regulatory authorities to ensure product safety, efficacy, and compliance. Meeting these regulatory requirements can be challenging for both nutraceutical companies and CDMOs. Nutraceutical products are subject to rigorous regulatory scrutiny to ensure consumer safety and product quality. Compliance with regulations such as Good Manufacturing Practices (GMP), labeling requirements, and product claims can be demanding for CDMOs. The need to adhere to diverse regional or international regulations can pose challenges in terms of consistency and efficiency. The regulatory landscape for nutraceuticals is continuously evolving. New regulations, guidelines, and labeling requirements are introduced, and existing regulations may undergo revisions. Keeping up with these changes and ensuring compliance can be time-consuming and resource-intensive for CDMOs, potentially impacting their operations and timelines. The nutraceutical industry operates in different regions and countries, each with its own regulatory framework. CDMOs that offer services globally need to navigate through a multitude of regulatory requirements, which can differ significantly from one market to another. Adhering to these variations adds complexity and increases the burden on CDMOs. While regulatory compliance challenges can pose a restraint in the nutraceuticals CDMO market, it is important to note that these challenges can also present opportunities for CDMOs to differentiate themselves by providing regulatory expertise and ensuring compliance for their clients.

Tablets & Capsules: Pillars of Nutraceutical Delivery

The nutraceuticals CDMO market is segmented by dosage forms, including tablets & capsules, powder, softgel, and others. Each dosage form has its own characteristics and benefits, catering to different consumer preferences and requirements. Tablets and capsules are one of the most common dosage forms in the nutraceutical industry. They offer convenience, precise dosing, and ease of consumption. These dosage forms are popular among consumers due to their familiarity and ease of incorporating into daily routines. Tablets and capsules accounted for a significant revenue percentage in the nutraceuticals CDMO market. The demand for tablets and capsules is expected to continue due to their widespread use and consumer preference for traditional solid dosage forms. The others category includes various innovative and emerging dosage forms in the nutraceuticals CDMO market, such as gummies, liquids, sprays, and sublingual formulations. These dosage forms offer unique delivery mechanisms and consumer experiences. The others segment is characterized by niche products and is expected to witness notable growth, driven by consumer demand for novel and convenient dosage formats.

Manufacturing and Packaging: Leading the Nutraceuticals CDMO Market

Manufacturing and packaging services encompass the production and packaging of nutraceutical products at scale. This includes processes such as blending, encapsulation, tableting, labeling, and packaging. These services are crucial for ensuring efficient and compliant manufacturing operations. Manufacturing and packaging services are anticipated to hold a significant revenue percentage due to the demand for reliable and high-quality production capabilities. Regulatory compliance services in the nutraceuticals CDMO market are expected to witness a relatively high CAGR due to their critical role in ensuring market access and consumer trust. These services play a vital role in helping nutraceutical products meet the stringent requirements and standards set by regulatory authorities. They involve navigating complex regulatory frameworks, obtaining necessary certifications, conducting audits, and ensuring product safety and compliance. The increasing regulatory scrutiny on the nutraceutical industry, coupled with the rising focus on consumer safety and product quality, drives the demand for robust regulatory compliance services. As the regulatory landscape continues to evolve and become more stringent, nutraceutical companies rely on CDMOs specializing in regulatory compliance to navigate these complexities effectively.

North America: Leader in Revenue and Market Presence

North America holds a significant revenue share in the nutraceuticals CDMO market, driven by its robust market presence, advanced manufacturing capabilities, and well-defined regulatory framework. This strong market position can be attributed to the increasing consumer demand for dietary supplements and functional foods, driven by factors such as the growing focus on preventive healthcare, rising health consciousness, and the adoption of wellness-oriented lifestyles. Asia Pacific emerges as a dynamic and high-growth region in the nutraceuticals CDMO market, fueled by various factors that drive the demand for nutraceutical products. The region's large population base, rising disposable income, shifting lifestyles, and the growing middle class create a fertile market landscape for nutraceuticals. Countries like China, Japan, and India play a pivotal role in driving the market growth in the Asia Pacific region. With its massive population, China presents substantial opportunities for nutraceuticals CDMOs to cater to the increasing consumer demand. The rising middle class in the country, coupled with a growing focus on health and wellness, has led to a surge in demand for dietary supplements and functional foods. Similarly, Japan has a well-established nutraceutical market, driven by the aging population and the cultural emphasis on preventive healthcare. India, with its expanding middle class and rising health awareness, is also a key contributor to the region's market growth.

Competitive Landscape

The Nutraceuticals CDMO market features a competitive landscape with key players such as Catalent, Lonza Group, Royal DSM, BASF, Kerry Group, Archer Daniels Midland, Glanbia, Capsugel, Aenova Group, NutraScience Labs, Nutragenesis, Pharmavite, SirioPharma, Balchem Corporation, and SirioPharma International. These companies provide a wide range of services including formulation development, manufacturing, packaging, and quality control for nutraceutical products. The market's competitive trends are driven by factors such as innovation, technological advancements, geographic expansion, strategic partnerships, and acquisitions aimed at enhancing capabilities and expanding service offerings.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofNutraceuticals CDMO market are as follows:

• Research and development budgets of manufacturers and government spending

• Revenues of key companies in the market segment

• Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Nutraceuticals CDMO market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Dosage Forms

• Tablets & Capsules
• Powder
• Softgel
• Others

Services

• Product Formulation and Development
• Manufacturing and Packaging
• Research and Development (R&D)
• Regulatory Compliance
• Others

Company Size

• Small Companies
• Mid-Sized Companies
• Large Companies

Region Segment (2021-2031; US$ Million)

• North America
• U.S.
• Canada
• Rest of North America
• UK and European Union
• UK
• Germany
• Spain
• Italy
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Africa
• Rest of Middle East and Africa

Key questions answered in this report:

• What are the key micro and macro environmental factors that are impacting the growth of Nutraceuticals CDMO market?

• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

• Estimated forecast and market projections up to 2031.

• Which segment accounts for the fastest CAGR during the forecast period?

• Which market segment holds a larger market share and why?

• Are low and middle-income economies investing in the Nutraceuticals CDMO market?

• Which is the largest regional market for Nutraceuticals CDMO market?

• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

• Which are the key trends driving Nutraceuticals CDMO market growth?

• Who are the key competitors and what are their key strategies to enhance their market presence in the Nutraceuticals CDMO market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Nutraceuticals CDMO Market
• 2.2. Global Nutraceuticals CDMO Market, By Dosage Forms, 2022 (US$ Million)
• 2.3. Global Nutraceuticals CDMO Market, By Services, 2022 (US$ Million)
• 2.4. Global Nutraceuticals CDMO Market, By Company Size, 2022 (US$ Million)
• 2.5. Global Nutraceuticals CDMO Market, By Geography, 2022 (US$ Million)
• 2.6. Attractive Investment Proposition by Geography, 2022

3. Nutraceuticals CDMO Market: Competitive Analysis

• 3.1. Market Positioning of Key Nutraceuticals CDMO Market Vendors
• 3.2. Strategies Adopted by Nutraceuticals CDMO Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2022 Versus 2031

4. Nutraceuticals CDMO Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Nutraceuticals CDMO Market Value, 2021 - 2031, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2022 Versus 2031
• 5.3. Market Segmentation
  • 5.3.1. Tablets & Capsules
  • 5.3.2. Powder
  • 5.3.3. Softgel
  • 5.3.4. Others

6. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2022 Versus 2031
• 6.3. Market Segmentation
  • 6.3.1. Product Formulation and Development
  • 6.3.2. Manufacturing and Packaging
  • 6.3.3. Research and Development (R&D)
  • 6.3.4. Regulatory Compliance
  • 6.3.5. Others

7. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2022 Versus 2031
• 7.3. Market Segmentation
  • 7.3.1. Small Companies
  • 7.3.2. Mid-Sized Companies
  • 7.3.3. Large Companies

8. North America Nutraceuticals CDMO Market, 2021-2031, USD (Million)

• 8.1. Market Overview
• 8.2. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
• 8.3. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
• 8.4. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
• 8.5.Nutraceuticals CDMO Market: By Region, 2021-2031, USD (Million)
  • 8.5.1.North America
    • 8.5.1.1. U.S.
      • 8.5.1.1.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 8.5.1.1.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 8.5.1.1.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 8.5.1.2. Canada
      • 8.5.1.2.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 8.5.1.2.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 8.5.1.2.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 8.5.1.3. Rest of North America
      • 8.5.1.3.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 8.5.1.3.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 8.5.1.3.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)

9. UK and European Union Nutraceuticals CDMO Market, 2021-2031, USD (Million)

• 9.1. Market Overview
• 9.2. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
• 9.3. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
• 9.4. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
• 9.5.Nutraceuticals CDMO Market: By Region, 2021-2031, USD (Million)
  • 9.5.1.UK and European Union
    • 9.5.1.1. UK
      • 9.5.1.1.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 9.5.1.1.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 9.5.1.1.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 9.5.1.2. Germany
      • 9.5.1.2.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 9.5.1.2.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 9.5.1.2.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 9.5.1.3. Spain
      • 9.5.1.3.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 9.5.1.3.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 9.5.1.3.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 9.5.1.4. Italy
      • 9.5.1.4.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 9.5.1.4.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 9.5.1.4.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 9.5.1.5. France
      • 9.5.1.5.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 9.5.1.5.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 9.5.1.5.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 9.5.1.6. Rest of Europe
      • 9.5.1.6.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 9.5.1.6.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 9.5.1.6.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)

10. Asia Pacific Nutraceuticals CDMO Market, 2021-2031, USD (Million)

• 10.1. Market Overview
• 10.2. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
• 10.3. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
• 10.4. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
• 10.5.Nutraceuticals CDMO Market: By Region, 2021-2031, USD (Million)
  • 10.5.1.Asia Pacific
    • 10.5.1.1. China
      • 10.5.1.1.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 10.5.1.1.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 10.5.1.1.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 10.5.1.2. Japan
      • 10.5.1.2.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 10.5.1.2.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 10.5.1.2.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 10.5.1.3. India
      • 10.5.1.3.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 10.5.1.3.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 10.5.1.3.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 10.5.1.4. Australia
      • 10.5.1.4.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 10.5.1.4.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 10.5.1.4.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 10.5.1.5. South Korea
      • 10.5.1.5.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 10.5.1.5.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 10.5.1.5.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 10.5.1.6. Rest of Asia Pacific
      • 10.5.1.6.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 10.5.1.6.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 10.5.1.6.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)

11. Latin America Nutraceuticals CDMO Market, 2021-2031, USD (Million)

• 11.1. Market Overview
• 11.2. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
• 11.3. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
• 11.4. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
• 11.5.Nutraceuticals CDMO Market: By Region, 2021-2031, USD (Million)
  • 11.5.1.Latin America
    • 11.5.1.1. Brazil
      • 11.5.1.1.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 11.5.1.1.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 11.5.1.1.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 11.5.1.2. Mexico
      • 11.5.1.2.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 11.5.1.2.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 11.5.1.2.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 11.5.1.3. Rest of Latin America
      • 11.5.1.3.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 11.5.1.3.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 11.5.1.3.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)

12. Middle East and Africa Nutraceuticals CDMO Market, 2021-2031, USD (Million)

• 12.1. Market Overview
• 12.2. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
• 12.3. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
• 12.4. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
• 12.5.Nutraceuticals CDMO Market: By Region, 2021-2031, USD (Million)
  • 12.5.1.Middle East and Africa
    • 12.5.1.1. GCC
      • 12.5.1.1.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 12.5.1.1.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 12.5.1.1.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 12.5.1.2. Africa
      • 12.5.1.2.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 12.5.1.2.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 12.5.1.2.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)
    • 12.5.1.3. Rest of Middle East and Africa
      • 12.5.1.3.1. Nutraceuticals CDMO Market: By Dosage Forms, 2021-2031, USD (Million)
      • 12.5.1.3.2. Nutraceuticals CDMO Market: By Services, 2021-2031, USD (Million)
      • 12.5.1.3.3. Nutraceuticals CDMO Market: By Company Size, 2021-2031, USD (Million)

13. Company Profile

• 13.1. Catalent, Lonza Group
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Portfolio
  • 13.1.4. Strategic Initiatives
• 13.2. Royal DSM
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Portfolio
  • 13.2.4. Strategic Initiatives
• 13.3. BASF
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Portfolio
  • 13.3.4. Strategic Initiatives
• 13.4. Kerry Group
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Portfolio
  • 13.4.4. Strategic Initiatives
• 13.5. Archer Daniels Midland
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Portfolio
  • 13.5.4. Strategic Initiatives
• 13.6. Glanbia
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Portfolio
  • 13.6.4. Strategic Initiatives
• 13.7. Capsugel
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Portfolio
  • 13.7.4. Strategic Initiatives
• 13.8. Aenova Group
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Portfolio
  • 13.8.4. Strategic Initiatives
• 13.9. NutraScience Labs
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Portfolio
  • 13.9.4. Strategic Initiatives
• 13.10. Nutragenesis
  • 13.10.1. Company Overview
  • 13.10.2. Financial Performance
  • 13.10.3. Product Portfolio
  • 13.10.4. Strategic Initiatives
• 13.11. Pharmavite
  • 13.11.1. Company Overview
  • 13.11.2. Financial Performance
  • 13.11.3. Product Portfolio
  • 13.11.4. Strategic Initiatives
• 13.12. SirioPharma
  • 13.12.1. Company Overview
  • 13.12.2. Financial Performance
  • 13.12.3. Product Portfolio
  • 13.12.4. Strategic Initiatives
• 13.13. Balchem Corporation
  • 13.13.1. Company Overview
  • 13.13.2. Financial Performance
  • 13.13.3. Product Portfolio
  • 13.13.4. Strategic Initiatives
• 13.14. SirioPharma International
  • 13.14.1. Company Overview
  • 13.14.2. Financial Performance
  • 13.14.3. Product Portfolio
  • 13.14.4. Strategic Initiatives
• 13.15. Other Notable Players
  • 13.15.1. Company Overview
  • 13.15.2. Financial Performance
  • 13.15.3. Product Portfolio
  • 13.15.4. Strategic Initiatives